Latest news from American Society of Nephrology (ASN) on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/kidney-week-2024-live-event-october-25th/?sc=rsin /articles/kidney-week-2024-live-event-october-25th/?sc=rsin Thu, 21 Nov 2024 13:00:29 EST Kidney Week 2024 Live Event: October 25th - Day #2 - 10/25/2024 American Society of Nephrology (ASN) /articles/obesity-management-and-kidney-health-live-expert-panel/?sc=rsin /articles/obesity-management-and-kidney-health-live-expert-panel/?sc=rsin Thu, 21 Nov 2024 13:00:27 EST Obesity Management and Kidney Health: Live Expert Panel - Live Event. 09/16/2024. American Society of Nephrology (ASN) /articles/kidney-week-2024-live-event-october-25th2/?sc=rsin /articles/kidney-week-2024-live-event-october-25th2/?sc=rsin Thu, 21 Nov 2024 13:00:11 EST Kidney Week 2024 Live Event: October 24th - Day #1 - 10/24/2024 American Society of Nephrology (ASN) /articles/prabir-roy-chaudhury-md-phd-fasn-to-become-next-president-of-the-american-society-of-nephrology/?sc=rsin /articles/prabir-roy-chaudhury-md-phd-fasn-to-become-next-president-of-the-american-society-of-nephrology/?sc=rsin Sun, 27 Oct 2024 12:00:00 EST Dr. Roy-Chaudhury will head up an organization--with nearly 21,000 health professionals representing 140 countries--dedicated to leading the fight against kidney diseases. American Society of Nephrology (ASN) /articles/trial-assesses-antibody-therapy-for-chronic-active-antibody-mediated-kidney-transplant-rejection/?sc=rsin /articles/trial-assesses-antibody-therapy-for-chronic-active-antibody-mediated-kidney-transplant-rejection/?sc=rsin Sat, 26 Oct 2024 19:30:00 EST Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/preclinical-studies-test-novel-gene-therapy-for-treating-iga-nephropathy/?sc=rsin /articles/preclinical-studies-test-novel-gene-therapy-for-treating-iga-nephropathy/?sc=rsin Sat, 26 Oct 2024 19:30:00 EST IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition's pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/researchers-test-imlifidase-enzyme-versus-plasma-exchange-in-removing-donor-specific-antibodies-in-kidney-transplant-rejection-trial/?sc=rsin /articles/researchers-test-imlifidase-enzyme-versus-plasma-exchange-in-removing-donor-specific-antibodies-in-kidney-transplant-rejection-trial/?sc=rsin Sat, 26 Oct 2024 19:30:00 EST For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)--a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23-27. American Society of Nephrology (ASN) /articles/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-2/?sc=rsin /articles/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-2/?sc=rsin Sat, 26 Oct 2024 13:30:00 EST The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23-27. American Society of Nephrology (ASN) /articles/how-the-novel-antibody-felzartamab-impacts-iga-nephropathy/?sc=rsin /articles/how-the-novel-antibody-felzartamab-impacts-iga-nephropathy/?sc=rsin Fri, 25 Oct 2024 19:30:00 EST IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients' kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab's potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/do-certain-diabetes-drugs-increase-the-risk-of-acute-kidney-injury-in-patients-taking-anti-cancer-therapies2/?sc=rsin /articles/do-certain-diabetes-drugs-increase-the-risk-of-acute-kidney-injury-in-patients-taking-anti-cancer-therapies2/?sc=rsin Fri, 25 Oct 2024 19:30:00 EST Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA-associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA-associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/researchers-integrate-multiple-protein-markers-to-predict-health-outcomes-in-individuals-with-chronic-kidney-disease/?sc=rsin /articles/researchers-integrate-multiple-protein-markers-to-predict-health-outcomes-in-individuals-with-chronic-kidney-disease/?sc=rsin Fri, 25 Oct 2024 19:30:00 EST Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases' (NIDDK's) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/global-national-and-regional-trends-in-the-burden-of-chronic-kidney-disease-among-women/?sc=rsin /articles/global-national-and-regional-trends-in-the-burden-of-chronic-kidney-disease-among-women/?sc=rsin Fri, 25 Oct 2024 19:30:00 EST A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/heart-and-kidney-outcomes-after-canagliflozin-treatment-in-older-adults/?sc=rsin /articles/heart-and-kidney-outcomes-after-canagliflozin-treatment-in-older-adults/?sc=rsin Fri, 25 Oct 2024 19:30:00 EST Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 - 27. American Society of Nephrology (ASN) /articles/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-1/?sc=rsin /articles/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-1/?sc=rsin Fri, 25 Oct 2024 13:30:00 EST The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23-27. American Society of Nephrology (ASN) /articles/kidney-week-2024-special-media-event-insights-on-rapidly-evolving-kidney-transplant-policy-landscape/?sc=rsin /articles/kidney-week-2024-special-media-event-insights-on-rapidly-evolving-kidney-transplant-policy-landscape/?sc=rsin Thu, 24 Oct 2024 20:15:00 EST On Thursday, Oct. 24 from 4:30-5:15 PM PT (7:30-8:15 PM ET), ASN will host an open-format discussion session - for media only - featuring several of the world's leading transplant nephrology researchers, care providers, and public policy experts. American Society of Nephrology (ASN) /articles/the-clinical-significance-of-microvascular-inflammation-after-kidney-transplantation/?sc=rsin /articles/the-clinical-significance-of-microvascular-inflammation-after-kidney-transplantation/?sc=rsin Thu, 24 Oct 2024 19:30:00 EST Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23- 27. American Society of Nephrology (ASN) /articles/asn-kidney-week-2024-wire-meeting/?sc=rsin /articles/asn-kidney-week-2024-wire-meeting/?sc=rsin Wed, 23 Oct 2024 12:15:54 EST ASN Kidney Week 2024 Wire Meeting Sent. American Society of Nephrology (ASN) /articles/american-society-of-nephrology-launches-the-glomerular-diseases-collaborative-gd-c-to-address-gaps-in-knowledge-and-barriers-in-the-care-of-people-with-glomerular-diseases/?sc=rsin /articles/american-society-of-nephrology-launches-the-glomerular-diseases-collaborative-gd-c-to-address-gaps-in-knowledge-and-barriers-in-the-care-of-people-with-glomerular-diseases/?sc=rsin Tue, 01 Oct 2024 14:05:42 EST Chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide, amounting to 800 million individuals.1 Glomerular diseases (GD), excluding diabetic nephropathy, account for approximately 25% of the cases of kidney diseases worldwide.2 Given the magnitude of long-term morbidity from GD-- particularly the frequent manifestation in younger patients--diagnosing it efficiently and optimizing management to control diseases and prevent progressive kidney diseases is paramount. American Society of Nephrology (ASN) /articles/kidney-week-2024-to-explore-a-world-without-kidney-diseases/?sc=rsin /articles/kidney-week-2024-to-explore-a-world-without-kidney-diseases/?sc=rsin Mon, 30 Sep 2024 08:35:36 EST Largest Global Gathering of Kidney Professionals Expands Program to Include More Breaking Research and Focused Discussions on Key Public Health and Policy Issues American Society of Nephrology (ASN) /articles/asn-kidney-health-guidance-on-the-management-of-obesity-in-persons-living-with-kidney-diseases2/?sc=rsin /articles/asn-kidney-health-guidance-on-the-management-of-obesity-in-persons-living-with-kidney-diseases2/?sc=rsin Wed, 18 Sep 2024 14:05:50 EST ASN Kidney Translation Series podcast episode, led by Matt Sparks, related to the ASN New Initiative Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases. American Society of Nephrology (ASN)